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!! !Figure 1.1. TSC mediated signaling in the CNS. This cartoon of TSC mediated signaling has been simplified to highlight 
the demonstrated biologic roles for TSC mediated mTOR signaling in the nervous system. 
Figure 1.1. TSC mediated signaling in the CNS. This cartoon of TSC 
mediated signaling has been simplified to highlight the demonstrated biologic 


































          Proliferation              Differentiation    Maturation !
Figure 1.2. Morphological and antigenic markers for 
oligodendroglia during development. The differentiation of 
oligodendrocytes from their progenitors follows a stepwise 
morphological transformation from bipolar progenitors to pro-
oligodendrocytes bearing multiple processes (immature), 
membrane-sheath-bearing mature oligodendrocytes, and, finally, 
myelinating oligodendrocytes. Accompanying this morphological 
change is the sequential expression of molecular markers: A2B5 
antigen, PDGFR and chondroitin sulphate proteoglycan NG2 in 
progenitors, O4 antigen in pro-oligodendrocytes, 
galactocerebroside (GC or O1 antigen) and CNPase in mature 
oligodendrocytes, and most myelin proteins — MAG, MBP, and 
PLP – in myelinating oligodendrocytes. These morphological and 
expression changes may be in response to extrinsic factors 
(modified from Zhang 2002) 
NRG/PDGF-A/CXCL1/FGF        FGF/IGF             TH/NRG!
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Figure 2.1. Without growth factor amplification and synchronization of 
the OPC lineage, there is no consistent quantitative effect of the 
experimental conditioned media despite qualitative differences observed 






























































Control Control + Rapa 
Mutant Mutant + Rapa 
Figure 3.1. Representative electron 
microscopic (EM) images of mutant and 
control mice corpus callosum, treated or 
untreated with rapamycin from P7. Without 
treatment, the mutant axons are enlarged and 
disorganized. Scale bar = 500 µm 
Figure 3.1. Representative electron microscopic (EM) images of 
mutant and control mice corpus callosum, treated or untreated with 
rapamycin from P7. Without treatment, the mutant axons are 





Figure 3.2. A. The axon diameter of the untreated mutant group was 
significantly increased (control, 0.55 ± 0.01, n = 497; mutant = 0.75 ± 
0.02, n = 173). This increase was reversible by rapamycin treatment 
(control Tx, 0.56 ± 0.01, n = 673; mutant Tx, 0.49 ± 0.01, n = 262). B. 
The g-ratio of the untreated mutant group was increased, indicating 
relatively thinner myelin (control, 0.61 ± 0.008 vs. mutant = 0.56 ± 
0.006) . Rapamycin treatment inhibited this increase in the mutants but 
had no effect on the control group g-ratio (treated control, 0.56 ± 0.01 
vs. mutant g-ratio, 0.53 ± 0.01). C. The g-ratio across equal diameter 
axons were not different across the groups. D. The percentage of 
unmyelinated axons within the 0.45 µm-0.55 µm were increased in the 









!Figure 3.3. At P14, Plp-eGFP mutant and control mice show no significant differences in the number of eGFP+ oligodendrocytes in the corpus callosum. Morphology of the individual plp+ oligodendrocyte looks indistinguishable. 
L=lateral, M=medial, CC=corpus callosum At P21, there was a dramatic 
increase in eGFP+ cells in the control brains that was not seen in the mutant 
brains. The boxed grey matter and dash boxed white matter corpus callosum 
areas are quantified in figure 3.4. The morphology of myelinating 
oligodendrocyte was still not different between the two groups. Scale bar in 
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Figure 3.7. CTGF is upregulated in vitro. A. Ctgf mRNA transcripts are upregulated when neurons 
lose approximately 80% Tsc2. B. representative western blot showing upregulation of CTGF 
protein in neurons with Tsc2 knockdown. Overnight rapamycin treatment can reverse this increase 
showing mTOR-dependency of CTGF regulation. C. Three independent western blot experiments 
were quantified to show the upregulation in Tsc2-deficient neurons and reversal with rapamycin 
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Figure 3.9. Immunostaining for CTGF 
in egfp-plp control and mutant brains 
shows CTGF is expressed along the 
grey-white matter border. Gray scale 
image shows the differences in number 
and intensity of CTGF expression. At 
P21, the CTGF levels remain high in the 
mutants. CTGF-positive cell numbers 
are increased by 1.4-fold in the mutants. 














Figure 3.10. Mutant brains show co-localization of pS6 
and CTGF along the grey-white matter border. Scale 













































Figure 3.11. CTGF treated OPC cultures failed to express MBP in dosage dependent 
manner. Without CTGF addition, the OPCs spontaneously differentiated into MBP 
expressing oligodendrocytes in 4 days in vitro. CTGF treated cells that failed to 
differentiated all expressed olig2, showing they were lineage committed but remained at 
immature stage. In contrast, the control culture with MBP-positive cells had olig2-
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Figure 3.13. CT CM and TSH CM treated oligodendrocytes were stained for pS6, a 
marker for mTOR activity. Higher number of CT CM treated oligodendrocytes expressed 
pS6 compared to the TSH CM treated oligodendrocytes (CT CM, 101 ± 5.9; TSH CM, 
64.7 ± 4.6; p < 0.001) . CT CM treated oligodendrocyte appear morphologically further 
differentiated with multiprocesses compared to the TSH CM treated oligodendrocytes 














   








MBP PLP CTGF 
Control Mutant 
Figure 3.14. The optic and sciatic nerve from P21 eGFP-Plp+ 
control and mutant mice were stained for MBP and CTGF and 
showed no differences in myelination, oligodendrocyte numbers 
and CTGF expression. CTGF levels were almost undetectable in 



















Figure 3.15. Tuber and perituber brain sections 
resected from 1 year old TSC patient were stained 
with CTGF and pS6. All CTGF-positive cells were 
also pS6-positive (arrowhead) showing mTOR 
regulation. Not all pS6-expressing cells were 
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Figure 4.1. mRNA expression levels in 
oligodendrocyte after five days of lentivirus Tsc2 
knockdown. Increase in ER stress marker chop 
accompanies ~80% decrease in Tsc2 and 
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Figure 5.2. Rat hippocampal neurons were infected with 
GFP, full length flag-tagged TSC2, or TSC2 with mutations 
in the peroxisome targeting signal (RQ, RG, RW). 5 DIV, the 
neurons were stained with axonal marker Tau1 and 
categorized into no axon, one axon, multiple axon groups. 
PTS mutated TSC2 increased the multiple axon polarity and 
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a b s t r a c t
Over the past several years, the study of a hereditary tumor syndrome, tuberous sclerosis complex
(TSC), has shed light on the regulation of cellular proliferation and growth. TSC is an autosomal
dominant disorder that is due to inactivating mutations in TSC1 or TSC2 and characterized by benign
tumors (hamartomas) involving multiple organ systems. The TSC1/2 complex has been found to play
a crucial role in an evolutionarily-conserved signaling pathway that regulates cell growth: the
mTORC1 pathway. This pathway promotes anabolic processes and inhibits catabolic processes in
response to extracellular and intracellular factors. Findings in cancer biology have reinforced the
critical role for TSC1/2 in cell growth and proliferation. In contrast to cancer cells, in the CNS, the
TSC1/2 complex not only regulates cell growth/proliferation, but also orchestrates an intricate and
finely tuned system that has distinctive roles under different conditions, depending on cell type,
stage of development, and subcellular localization. Overall, TSC1/2 signaling in the CNS, via its
multi-faceted roles, contributes to proper neural connectivity. Here, we will review the TSC signaling
in the CNS.
! 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Introduction
TSC is a multisystem disorder, in which 90–95% of the affected
individuals have CNS symptoms or signs. Neurologically, TSC can
manifest with intellectual disability, behavioral abnormalities,
autism spectrum disorders (ASD), and seizures [1]. Epilepsy occurs
in 80–90% of all patients, often with medically refractory seizures.
Close to 45% of patients have mild-to-profound intellectual
disabilities and ASD occurs in up to 50% of patients [1,2]. TSC can
be diagnosed in the pre- or perinatal period [3], and many neuro-
pathological features such as cortical tubers and histological
abnormalities are present by the second trimester in utero indicat-
ing that neurological manifestations of the disease develop during
the embryonic period [4,5]. Clinical signs can be variable with
some individuals within a family having minimal symptoms while
others carrying the same mutation being severely affected.
The neuropathological findings in the brain usually take the
form of (1) subependymal nodules, (2) subependymal giant cell
astrocytomas (SEGA) and (3) cortical tubers [6]. Subependymal
nodules are lesions found along the wall of the lateral ventricles
in the brain. In 5–10% of cases, these benign lesions can grow into
SEGAs that block the circulation of cerebrospinal fluid resulting in
hydrocephalus. Tubers are made up of a collection of abnormally
large neurons and glia and are most commonly found in the
cerebral cortex. It has been proposed that the presence of cortical
tubers contribute to the severity of the disorder, but studies have
presented conflicting findings on which aspects of the tubers are
most critical indicators. More recent studies indicate that the
tuber volume is a better reflection of the severity of cognitive
impairment than tuber number alone, and also that the location
of the tubers (frontal/occipital/temporal/cerebellar) has differen-
tial associations with comorbid neuropsychiatric disorders [7–9].
Sophisticated analysis of the neuronal function of TSC1/2 genes
in vitro and in animal models has revolutionized our understand-
ing of the disease mechanisms and potential treatment options.
1.1. TSC1 and TSC2 protein complex
TSC1 (on chromosome 9) and TSC2 (on chromosome 16) are tu-
mor suppressor genes that integrate extrinsic and intrinsic signals
of the cellular energy status and growth. Proteins encoded by TSC1
and TSC2 genes, also known as hamartin and tuberin, respectively,
bind to each other to form a GTPase activating protein (GAP) com-
plex that plays a critical role in the regulation of protein synthesis,
controlling cell growth and size [10]. Both proteins are required for
the proper function of the complex, and thus a mutation in either
gene is sufficient to cause the clinical disease. TSC1 is required to
stabilize TSC2 and prevent its degradation. On the other hand,
the functional GAP domain resides in TSC2, making each protein
obligatory for each other’s functional role. In fact, studies in Dro-
sophila have shown that the Tsc1;Tsc2 double mutants phenocopy
either single mutants and that overexpression of both proteins is
0014-5793/$36.00 ! 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.febslet.2011.02.001
⇑ Corresponding author. Address: 300 Longwood Av. CLSB 13074 Boston, MA
02115, USA. Fax: +1 617 730 0279.
E-mail address: mustafa.sahin@childrens.harvard.edu (M. Sahin).
FEBS Letters 585 (2011) 973–980
journal homepage: www.FEBSLetters .org
! "UU!!
Author's personal copy
required to render a gain of function phenotype [11,12]. Nonethe-
less, patients with TSC2 mutations have a worse overall prognosis
than those with TSC1 mutations [13], and the conditional Tsc2
knockout mouse model has a more severe phenotype than the con-
ditional Tsc1 knockout in the same conditional genetic background
[14]. These differences could be due to the fact that the two pro-
teins have additional independent functions. Another possibility
is that, although both TSC1 and TSC2 are subject to ubiquitin-med-
iated degradation if not bound to each other, some enzymatic
activity of TSC2 remains and is able to carry out some of its func-
tion before its degradation. TSC1, which has no such catalytic do-
main, would be ineffective in suppressing mTOR activity on its
own [15]. Investigations into the protein interactors of TSC1/2 have
begun in non-neuronal cell lines [16–18], but the question of
which proteins interact with the TSC1/2 complex in CNS cells –
at different times during development and at different subcellular
locations – has not yet been explored.
The TSC1/2 complex can be regulated post-translationally by
several major signaling pathways in cells: PI3K-Akt, ERK and AMPK
(Fig. 1). The best-characterized function of the TSC1/2 complex is
as a downstream target of the phosphatidylinositol 3-kinase
(PI3K) pathway that becomes activated upon the binding of growth
factors (e.g. IGF or BDNF). Activated PI3K leads to recruitment of
PDK1 and the serine/threonine protein kinase Akt, and subsequent
phosphorylation/activation of Akt by PDK1. Activated Akt nega-
tively regulates TSC by directly phosphorylating TSC2 on five con-
sensus sites on human TSC2 [19–22]. A second kinase that can
phosphorylate and inhibit TSC2 is the extracellular signaling-regu-
lated kinase (ERK) [23]. ERK phosphorylation of TSC2 appears to be
particularly important for EphA-receptor mediated regulation of
TSC2 [24]. Both active Akt and ERK levels are found to be high in
TSC-related cortical tubers and SEGAs, and the inhibition of TSC2
by these kinases has been proposed to represent a post-transla-
tional mechanism that may further amplify the loss of the first al-
lele of the TSC gene [23,25]. In addition, AMP-activated protein
kinase (AMPK) can phosphorylate TSC2 on a different set of resi-
dues than Akt and ERK and potentially increase the ability of
TSC1/2 to inhibit the mTORC1 activity, thereby protecting cells
from excessive energy use during low energy states [26,27]. TSC1
is also negatively regulated by IKK-beta, which physically interacts
with and phophorylates TSC1 at its Ser487 and Ser511 residues in
response to inflammatory pathway activation [28]. Because
TSC1:TSC2 functions as a dimer, regulation of either protein most
likely affects its overall activity level. However, relatively little is
known about the post-translational modifications affecting the
TSC1 protein and the hierarchy of the regulatory modification on
the TSC1/2 complex, particularly those involving AMPK and IKK.
Furthermore, none of these post-translational modifications ap-
pear to affect the GAP activity of TSC2 per se, but they somehow
affect the ability of the TSC1/2 complex to act as a Rheb-GAP in
cells. Whether this effect is due to changes in subcellular localiza-
tion or other cellular mechanisms are not yet clear.
1.2. Downstream of TSC: mTORC1 and 2
When active, TSC2 inhibits Ras family GTPase Rheb by stimulat-
ing the conversion of Rheb-GTP to Rheb-GDP. Downstream targets
of Rheb include the serine–threonine kinase mammalian target of
rapamycin (mTOR), a central regulator of protein synthesis. mTOR
kinase exists in two distinct functional complexes, mTOR Complex
1 and mTOR Complex 2, defined by two groups of binding partners
(Fig. 1). mTORC1 is comprised of the core essential components
Raptor and LST8, while mTORC2 contains Rictor, LST8, and SIN1.
mTORC1 is bound strongly and is quickly inhibited by rapamycin,
Fig. 1. TSC mediated signaling in the CNS. This cartoon of TSC mediated signaling has been simplified to highlight the demonstrated biologic roles for TSC mediated mTOR
signaling in the nervous system.
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while mTORC2 inhibition requires prolonged rapamycin treat-
ment, which blocks mTORC2 assembly [29]. However, rapamycin
does not fully inhibit mTORC1 function, with some downstream
targets being more sensitive than others [30]. mTORC1 phosphor-
ylates and activates ribosomal S6 kinases (S6K1 and S6K2) and
inhibits the translational regulator 4E-BP1 – both events that pos-
itively regulate translation of 5’capped mRNAs. mTORC1 phosphor-
ylates S6K1 on Thr389, resulting in phosphorylation of its
downstream effectors that increase mRNA translation [31]. Activa-
tion of S6Ks leads to phosphorylation of ribosomal protein S6, elon-
gation factor 2 kinase (eEF-2K), programmed cell death protein 4
(PDCD4), and eIF4B, all of which result in increased protein synthe-
sis [32–35]. Unphosphorylated 4E-BP1 is bound to eukaryotic initi-
ation factor 4E (eIF4E), inhibiting its association with the eIF-4F
cap-binding complex, thereby blocking translation initiation [36].
When phosphorylated by mTORC1, 4E-BP1 dissociates from the
eIF4E complex, initiating mRNA translation [37,38]. Thus, without
the functional TSC complex, mTORC1 is hyperactive, resulting in
constitutively phosphorylated S6 protein, disinhibited protein syn-
thesis, and subsequent cell growth [39,40]. As a central regulator of
cell growth, mTORC1 is sensitive to nutrient and redox states of the
cells, and more recently has been shown to be specifically respon-
sive to amino acids through a not yet well defined pathway involv-
ing the Rag GTPases [41–43]. The presence of amino acids
somehow alters the nucleotide-bound state of a heterodimeric
Rag complex at lysosomal membranes, and this creates a docking
site for mTORC1 [42]. Once at the lysosomal membrane, mTORC1
encounters Rheb, but it is not yet clear how or if Rheb is targeted
to the same endomembranes as mTORC1 and Rag proteins.
Whether neuronal mTORC1 has specific function at the lysosome
has yet to be investigated, and it would be interesting to find out
other cellular localization sites of TSC1/2 and mTORC1 and their
relevance to the function of this signaling pathway.
Our understanding of mTORC2 is nascent when compared to
mTORC1 (especially in the CNS), but it is emerging as a critical
component of the PI3K/mTOR pathway. While TSC1/2 negatively
regulates mTORC1, it promotes mTORC2 activity in a Rheb-inde-
pendent manner that might involve the direct binding of the
TSC1/2 complex to components of the mTORC2 complex [44–46]
Once active, mTORC2 phosphorylates and activates AKT, leading
to phosphorylation of its downstream effectors including TSC2
[47]. There also appears to be crosstalk between mTORC1 and
mTORC2, as S6K1 phosphorylates and inhibits Rictor [48]. Interest-
ingly, loss of the TSC1 or TSC2 leads to a unique cellular scenerio in
which mTORC1 is activated and mTORC2 is attenuated. An impor-
tant implication of these findings is that the ideal treatment for
loss of TSC1/2 may require not only mTORC1 inhibition but also
mTORC2 activation. As most of these initial studies were per-
formed in non-neuronal cells, it has yet to be seen whether the
pathway is conserved in the CNS and how the intricate balance be-
tween the two mTOR complexes affects neuronal function. Studies
in the last few years have begun to shed light on the role of these
proteins in several aspects of neural development and function,
and it is becoming clear that TSC1/2 protein complex is a master
regulator of neuronal connectivity.
2. Roles of TSC complex in neuronal development and function
2.1. Axon specification
In the CNS, almost all neurons have a single axon and multiple
dendrites. Establishing this unique polarized structure is critical for
proper function and directionality of the flow of information with-
in the CNS. Interestingly, TSC pathway components are expressed
in neurons in a polarized manner [49–51]. Overexpression of
Tsc1 and Tsc2 suppresses axon formation while loss of Tsc1 or
Tsc2 function leads to increased axon number [49]. This critical
function of TSC1/2 appears to be related to its ability to regulate
levels of a number of proteins such as SAD-A, a kinase required
for axon formation in the mouse brain. When TSC is non-func-
tional, SAD-A proteins levels are increased in neurons in an
mTOR-dependent manner [49]. Other proteins that are regulated
by TSC/mTORC1 include CRMP2, Tau1 and Rap1B, all of which
can play a role in neuronal polarity [50,51]. There are likely to be
other neurite proteins whose expression is regulated by TSC, and
the full repertoire of proteins regulated by TSC/mTORC1 in neurites
remains to be identified.
2.2. Axon guidance
One of the most critical steps in neural development is the for-
mation of precise neuronal networks. Importantly, there is growing
appreciation of the role of protein translation in axons as a crucial
substrate of axonal development. Axons have long been thought to
lack active translation as rough ER and polyribosomes are hardly
detectable in mammalian axons. However, axons severed from
their soma can synthesize proteins readily [52–54] and many func-
tional aspects of the axonal growth cone involve local mRNA trans-
lation. It is possible that monoribosome or other functional analogs
can be used to synthesize proteins in axons [55]. Using either com-
partmentalized culture systems or direct laser capture of axons, re-
cent studies have revealed that hundreds of mRNAs are present in
axons [56,57]. Blockade of local translation not only affects growth
cone collapse and turning in culture systems but also impairs nor-
mal axon guidance, circuit development and regeneration [24,58–
60]. Indeed, Sema3A-induced growth cone collapse, which requires
local translation of RhoA, is blocked by rapamycin treatment [61].
Many other guidance cues, including netrin-1, slit1, ephrins, regu-
late axonal protein synthesis through either ERK- and/or mTOR-
dependent pathways [24,62,63].
One of the first pieces of evidence for aberrant axon guidance in
TSC-deficient neurons came from Drosophila. The investigators
showed that increases and decreases in TOR signaling via Rheb cor-
related, respectively with changes in synaptic overgrowth and
reduction [64]. Additionally, mutant photoreceptor neurons lack-
ing Tsc1 formed disorganized lamina plexus and aberrant projec-
tions into the medulla [64]. More detailed molecular study done
using a Tsc2 heterozygous mouse model has shown that haploin-
sufficiency of Tsc is sufficient to produce aberrant neuronal projec-
tions. Axons of retinal ganglion cells find their synaptic targets in
the lateral geniculate nucleus of the thalamus by interacting with
a group of repulsive axon guidance molecules called ephrins,
which bind to cell surface receptors called Eph receptors. Tsc2 het-
erozygous axons display abnormal growth cone collapse in re-
sponse to ephrins [24]. Therefore, abnormal collapse of these
structures in Tsc haploinsufficient neurons and subsequent incor-
rect projections into the thalamus show the intimate interweaving
of the TSC pathway with Ephrin/Eph pathway, which may play a
similar role in other axon projections.
2.3. Synapse formation and function
It has long been recognized that neuronal soma size and den-
dritic growth positively correlate with innervation and the release
of trophic factors. In particular, BDNF is reported to be involved in
regulating dendritic complexity and soma size [65]. However, the
signaling cascades mediating the effects of such trophic factors
are not well understood. Recently, several groups have reported
that the PI3K/Akt/mTOR pathway regulates soma size, dendritic
arborization and spine morphogenesis [66–68]. Activation of
PI3K and Akt both increased cell size and dendritic complexity
J.M. Han, M. Sahin / FEBS Letters 585 (2011) 973–980 975
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while inhibition of endogenous PI3K and Akt decreased cell size
and dendritic branching [66,67]. These effects appear to be medi-
ated through mTOR, as treatment with rapamycin or mTOR RNAi
decreased dendritic branching [66,67]. Interestingly, Tsc1 or Tsc2
loss increased spine length and head width and decreased the den-
sity of dendritic spines in hippocampal slice cultures [68]. Similar
decrease in spine density was observed in Tsc1 null neurons
in vivo [69].
In addition to structural changes in dendrites, the mTOR path-
way is reported to play a role in post-synaptic AMPA receptor
expression [70]. In Tsc1 deficient hippocampal neurons, the
AMPA/NMDA receptor current ratio was significantly increased
relative to that in controls, suggesting an aberrant relative
enhancement of synaptic AMPA receptors [68]. In wild-type neu-
rons, the effect of mTOR activation on spine formation appears to
be immediate in induction of synapse associated proteins Arc, syn-
apsin I, PSD95, and GluR1 [71]. In this study, the investigators used
antidepressant ketamine to activate mTOR, which led to increased
spine density and increased EPSCs in response to 5-HT in prefrontal
cortical neurons [71]. Although the exact mechanism of how the
NMDA receptor antagonist ketamine regulates mTOR activation
is unclear, it requires ERK and/or Akt, suggesting that TSC is possi-
bly involved as well. Finally, staining of cortical tubers from TSC
patients has indicated a decrease in GluR2 and NR2A staining in
giant cells and dysplastic neuron cell bodies [72]. Whether these
changes also reflect a reduction in cell surface GluR2 and NR2A
expression and the mechanisms leading to these changes are not
yet clear. Together, the pre- and post-synaptic roles that the TSC/
mTOR pathway plays strongly indicate that abnormalities in this
pathway are likely to result in defects in synapse formation, elim-
ination and plasticity, likely correlating with the neurological and
developmental symptoms of TSC disease.
2.4. Axon regeneration
Regeneration potential of CNS axons following injury has been
limited at best. CNS axon regeneration research has focused on
inhibitory factors that have thwarted successful outgrowth of the
axons, but recently the TSC/mTOR pathway has emerged as a crit-
ical intrinsic modulator of the axon’s potential to regenerate after
injury. PI3K/AKT pathway is one of the major intracellular re-
sponses to neurotrophin regulated axon outgrowth and inhibition
of this pathway in neurons reduces the axon growth that occurs in
response to growth factor stimulation [73,74]. This intrinsic out-
growth signal may become diminished in adult neurons after
development has been completed and cannot be reactivated
post-injury. In fact, embryonic neurons display strong mTOR activ-
ity that then diminishes in adult neurons, and the remaining mTOR
activity in adult neurons is further suppressed by axonal injury
through a yet unknown negative regulator [75]. Consequently,
upon conditional deletion of PTEN or Tsc1 in retinal ganglion cells
(RGCs), with resulting mTOR activation, crushed axons exhibit ro-
bust long distance regeneration and increased cell survival [75].
This regenerative potential is not unique to the optic nerve, and
PTEN deletion is also able to enhance sprouting and outgrowth of
corticospinal neurons following spinal cord injury, ultimately
reforming presynaptic structures [76]. Since PTEN deletion facili-
tates the regenerated axons’ ability to grow slightly more robustly
than those lacking Tsc1, it is possible that there are other PTEN reg-
ulated targets such as GSK-3b that promote other necessary axon
growth functions such as microtubule assembly [77]. It was more
recently shown that intraocular inflammation induced oncomodu-
lin and elevation in intracellular cAMP levels, in combination with
PTEN deletion, are complementary in bolstering the long-distance
axon regeneration, showing the necessity for activation of parallel
injury response pathways for more extensive regrowth [78].
Nonetheless, the most critical component of the axon regeneration
appears to be mTORC1 dependent, probably because of its ability
to promote overall protein translation. Whether the regenerated
axons find the correct target and form functional synapses has
yet to be investigated, but the current knowledge of mTORC1’s role
in these processes predicts that a more precise and coordinated
type of modulation of mTORC1 activity may prove necessary dur-
ing the regeneration process rather than a complete hyperactiva-
tion by PTEN suppression.
2.5. Cellular stress
One of the critical homeostatic mechanisms that cells have
evolved against intracellular stress is Unfolded Protein Response
(UPR). In normal neurons, prolonged chemical induction of ER
stress leads to inhibition of the mTOR pathway. Inhibition of
PI3K pathway results in increased cleaved caspase-3, reflecting
activation of the apoptotic pathway, similar to the recently demon-
strated data with Tsc2-deficient cells [79,80]. Tsc loss results in
mTOR dependent ER stress response at baseline, and upon treat-
ment with stress-inducing agents such as thapsigargin, the Tsc2-
deficient cells exhibit a lowered threshold for induction of UPR-
regulated genes and mitochondrial cell death pathways. More
importantly, the lack of Tsc activity leads to increased expression
of the pro-apoptotic transcription factor CHOP (C/EBP homologous
protein), production of reactive oxygen species (ROS), and suscep-
tibility to apoptosis. Immunohistochemical analysis on human TSC
brain sections demonstrate similar upregulation in CHOP and
heme oxygenase (HO-1), suggesting that heightened ER stress
could lead to selective vulnerability of TSC-deficient neurons to
extrinsic insults such as seizures, hypoxia, and environmental tox-
ins. Given the reproducibility across cells types on which these
studies were performed (neurons, MEFs, kidney cells), it is likely
that other CNS cells such as astrocytes and oligodendrocytes would
also be susceptible to the damage.
Another cellular response regulated by mTOR is autophagy.
Autophagy is an evolutionarily conserved ‘‘self-eating’’ mechanism
responsible for the removal of long-lived proteins and damaged
organelles by the lysosome. During autophagy, double-membrane
autophagosomes sequester intracellular components and then fuse
with lysosomes to form autolysosomes in which cargo is degraded.
Under growth stimulating conditions, mTOR signaling is activated,
which results in inhibition of autophagy. Under starvation condi-
tions, mTOR is inhibited, leading to induction of autophagy. After
prolonged starvation, mTOR is reactivated, which reduces autoph-
agy and results in the formation of tubules and vesicles thereby
restoring lysosome numbers in the cell [81]. Both ER stress [82]
and oxidative stress [83] appear to induce autophagy through the
TSC/mTOR pathway. As most of these studies were performed in
non-neuronal cells, further studies will be needed to investigate
whether TSC1/2 plays similar roles in regulating neuronal
autophagy.
3. CNS mouse models of TSC
3.1. Heterozygous models
There are several mouse models of TSC, and although none
manifest the full complement of the CNS phenotype in humans –
cortical tubers, subependymal nodules or SEGAs – each has
provided valuable insight. The first heterozygous mouse models
of TSC established that haploinsufficiency of either Tsc1 or Tsc2
causes neurocognitive deficits such as impaired hippocampal-
dependent learning, social behavior, synaptic plasticity, learning
and memory [84,85]. Tsc2 heterozygous mice also exhibit
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abnormal mother–pup interaction as measured by ultrasonic
vocalizations (USV), establishing these mice as potential models
of autism [86]. These neuropsychiatric abnormalities are present
without obvious concomitant neuropathological alterations,
prompting more rigorous investigation of subtle molecular and
circuitry level changes. Heterozygous models display no clear ana-
tomic abnormality under pathologic evaluation, although Tsc2+/!
neurons do display abnormal axon guidance [24], providing
further support for the hypothesis that abnormal neuronal connec-
tivity may underlie the neurological symptoms in TSC disease.
3.2. Neuron-specific models of TSC
Neuron-specific knockout of Tsc1 in postmitotic neurons has
been generated using Cre recombinase under the Synapsin-1 pro-
moter (SynI-Cre) [87]. Tsc1flox/flox;SynICre mice are viable perina-
tally, but develop tremor and hyperactivity beginning the second
week of life and die starting approximately 4–6 weeks postnatally.
These mice exhibit several neuropathological abnormalities similar
to those seen in TSC patients including enlarged dysplastic neurons
throughout the cortex, hippocampus, and other subcortical grey
matter regions as well as spontaneous seizure episodes. mTORC1
inhibitor treatment has reversed some neuroanatomical abnormal-
ities associated with clinical TSC including reduction in neuron size
and improvements in biochemical/signaling profiles, as well as
clinical improvements in body weight, clasping behavior, tremor,
seizures and kyphosis [39]. Furthermore, when animals are taken
off treatment, myelination and other clinical improvements
remained intact for at least two more weeks, indicating that
regulation of neuronal mTORC1 is critical not only during neurode-
velopment but also for long term maintenance of neuronal
function.
Deletion of Tsc2 from radial glial precursors cells using hGFAP-
Cre transgenic mice results in lamination defects, cortical
enlargement, astrogliosis as well as myelination defects [88].
Tsc2flox/flox;hGFAP-Cremice exhibited severe compromise in survival
and profound seizure episodes, suggesting again that cortical
tubers are not necessary for the observed phenotypes.
3.3. Astrocyte-specific model of TSC
Another important observation made from Tsc1+/! and Tsc2+/!
mice was the increase in the numbers of astrocytes [89]. As homo-
zygous loss of Tsc1 or Tsc2 results in prenatal death, Gutmann and
colleagues generated Tsc1flox/flox;GFAP-Cremice to specifically inacti-
vate Tsc1 in astrocytes in order to study the impact of the complete
loss of Tsc in these cell types [90]. Tsc1flox/flox;GFAP-Cremice demon-
strated up to a six-fold increase in GFAP-immunoreactive cells and
subsequent enlargement of some cortical regions such as the hippo-
campus accompanied by alterations in neuronal organization [90].
Additionally, these mice developed electroencephalographically
confirmed seizures by two months of age, but they failed to mimic
additional manifestations of TSC such as cortical tubers or cortical
lamination defects. The neuropathological phenotypes in these
mice were mTORC1-dependent and treatable, as rapamycin treat-
ment prevented development of progressive astrogliosis, abnormal
neuronal organization, development of epilepsy and premature
death in these mice [91]. Epileptogenesis in these mice was attrib-
uted to the increases in extracellular glutamate levels due to
decreased astrocytic GLT-1 and GLAST glutamate transporters,
and treatment with ceftriaxone to increase the transporter expres-
sions in presymptomaticmice decreased excitotoxic neuronal death
and severity of epilepsy [92,93]. Interestingly, when the mice were
treated after the onset of seizures, ceftriaxone treatment and
subsequent increase in glutamate transporter expression failed to
have an effect on seizures, alluding to the importance of early
treatments to prevent permanent neuropathological changes [93].
Furthermore, there may be other astrocytic dysfunction or even
embryologic/perinatal alterations arising from TSC-deficiency that
may contribute to the seizures given that even the early postnatal
treatments did not prevent the seizures completely. Therefore, the
exact changes in the neuropathology and the critical time of
intervention to effectively prevent seizures require further
investigation.
3.4. Role of TSC in oligodendrocytes
Much of the focus in the field has been on astrocytes and neu-
rons, perhaps because of their direct contributions to epilepsy
and tuber formation. Nonetheless, the correlation between the
severity of cognitive impairments and degree of hypomyelination
has brought to surface that the TSC/mTOR pathway is also critical
in development and function of oligodendrocytes. Myelination def-
icits are commonly observed in the TSC brain, both focally within
tubers and more diffusely [94–96]. Focal white matter deficits
are frequently in the subcortical region underlying tubers, high-
lighted by ectopic neurons, loss of axons, giant cells, and large
astrocytes. More diffusely, this congenital defect persists through-
out adulthood, infiltrating numerous major intrahemispheric tracts
bilaterally causing approximately 15% reduction in white matter
volume [97]. Furthermore, diffusion tensor imaging studies indi-
cate that TSC patients have occult damage in the normal appearing
white matter and that this damage may contribute to neurocogni-
tive disability in these patients [96,98–100]. Despite its signifi-
cance, it has been unclear whether the defect in myelination is
cell-autonomous due to loss of TSC function in oligodendrocytes
or indirectly due to TSC-deficient neuronal dysfunction.
OLs proliferate, differentiate, and myelinate in independently
controlled events that require specific extrinsic cues for each stage
of their development. Of these, neuron-synthesized insulin-like
growth factor-1 (IGF-1) has been shown to affect all three aspects
of OL development [101,102]. Interaction of IGF-1 with IGF-1R on
OLs result in rapid transcription and de novo protein synthesis in
the OLs through PI3K/Akt, mTOR, and MEK/ERK pathway activation
as shown by respective pharmacological inhibition of each path-
way component [103]. mTOR activation is required for the termi-
nal differentiation of the oligodendorcyte precursor cells (OPCs)
by enabling intrinsic mechanisms to acquire OL-specific gene
expression [104]. Interestingly, mTORC1 and mTORC2 appear to
have distinct temporal roles in the process; mTORC1 targets
P70S6K1 and 4E-BP for phosphorylation at the onset of OPC differ-
entiation while mTORC2 substrate Akt Ser473 phosphorylation
was sustained through latter stages of differentiation [104]. Addi-
tionally, other recent studies have shown that hyperactivation of
the pathway in OL lineage cells either by selective deletion of PTEN
(Olig2-cre, Ptenfl/fl) or constitutive overexpression of Akt (PLP-Akt-
DD) both result in mTOR-dependent hypermyelination [105,106].
PI3K/mTOR pathway appears to regulate myelination by modulat-
ing the amount of protein translation; however, this process seems
to be limited to the developmental period, as Olig2-cre, Ptenfl/fl mice
did not exhibit greater remyelination following lysolecithin
induced demyelination [105].
Despite their lack of complete demonstration of the human TSC
phenotype, each animal model generated has given valuable
insight into the function of the TSC/mTOR pathway in each cell
type. Since in the CNS, each neuronal and glial cell type has
different functions, it is likely that TSC1/2 play a number of roles
in the development and function of each of these cell types.
Conditional and inducible knockout of Tsc1 and Tsc2 in specific cell
types and developmental periods is likely to provide important
insights into the CNS biology as well as the pathogenesis of TSC
disease.




Findings from TSC may also have implications for other condi-
tions in which mTORC1 is hyperactive. Such conditions include ge-
netic diseases such as Neurofibromatosis type 1 (NF1), Fragile X
Syndrome (FXS), and PTEN hamartoma syndrome, all of which
have been associated with ASDs, behavioral dysregulation, or intel-
lectual disability. In addition, there is evidence of mTORC1 activa-
tion in focal cortical dysplasias [107] and gangliogliomas [108].
NF1 occurs due to loss-of-function mutations in the NF1 tumor
suppressor gene. The NF1-encoded protein, neurofibromin, func-
tions as a Ras-GTPase activating protein (RasGAP). In both NF1-
deficient primary cells and human tumors, both ras and mTOR
are hyperactivated. In fact, the activation of mTORC1 is dependent
on endogenous ras activity in these cells [109]. Furthermore,
mTORC1 activity is essential for NF1-associated tumorigenesis
[110]. These data suggest that mTOR inhibitors may represent a
viable therapy for NF1-related malignancies.
FXS is the most common form of inherited intellectual disability
and a leading genetic cause of autism [111]. Accumulating evidence
over the last few years indicates that TSC and FMRP pathways inter-
act and share several common signaling components. However,
precisely how they interact remains an open question. On the one
hand, FMRP can be phosphorylated by S6K1, an enzyme down-
stream of TSC [112]. On the other hand, mTORC1 is hyperactive in
Fmr1 knockout neurons [113], and FMRP-deficient cells display in-
creased activity of PI3K, an enzyme upstream of TSC proteins [114].
These findings have led to the hypothesis that hyperactive PI3K/
mTORC1 signaling is pathogenic in FXS [113,115,116]. These impor-
tant similarities and differences between the two genetic diseases
justify further systematic analysis of these conditions using mouse
models.
The pathways regulating TSC function have been also impli-
cated in childhood neurological problems, particularly autism.
PTEN mutations have been detected in a subset of patients with
autism and macrocephaly [117]. Furthermore, when the PTEN gene
is deleted in subsets of differentiated neurons in the cerebral cor-
tex and hippocampus, mutant mice show a profound decrease in
social interaction and nesting [118]. At a cellular level, PTEN null
axonal processes are more exuberant and project to a broader area
compared to axons in wild-type mice. Taken together, these results
suggest that PTEN inactivation in differentiated neurons is associ-
ated with increased axonal growth, ectopic axonal projections, and
autistic-like behavior in mice. Importantly, rapamycin treatment
blocks the anatomical, cellular, and behavioral abnormalities in
these knock-out mice.
4. Future directions
Emerging evidence – from abnormal white matter on neuroim-
aging of TSC patients to deficits in axonal integrity in animal mod-
els – supports the hypothesis that TSC1/2 proteins play crucial
roles in neuronal connectivity. In past 20 years since the identifica-
tion of genetic cause of TSC disease, staggering insights into basic
cell biology as well as targeted therapies have been made. Based
on clinical trials [119], the U.S. Food and Drug Administration
has approved an mTOR inhibitor everolimus in November 2010
for treatment of SEGAs in TSC patients, who are not candidates
for surgical resection. At the same time, there is growing evidence
that TSC and rheb may have mTORC1-independent functions
[120,121]. As we experimentally dissect the TSC/mTOR pathway
using more precise genetic tools, the crucial role of this pathway
in multiple areas of neural development and function is becoming
clear. To accelerate this progress, it will be important to generate
animal models that more closely replicate human disease. Major
gaps in our knowledge include: (1) the genetic and non-genetic
modifiers of TSC disease that account for the remarkable variability
of expression within the human population; (2) cell type and sub-
cellular location specific roles of TSC1/2 and their effectors; (3)
mTORC1-independent aspects of TSC regulation of neuronal func-
tion; (4) the interplay between the different neurological symp-
toms of TSC disease (epilepsy, autism etc); (5) the relationship
between neuronal energetics and the TSC/mTOR pathway. Studies
that address such questions will shed light on the interaction be-
tween TSC1/2 genes, environment, and neurodevelopment.
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Tuberous sclerosis complex (TSC) is an autosomal dominant disease 
characterized by the presence of benign tumors called hamartomas, 
which can affect virtually every organ system of the body, including 
the brain (where hamartomas are known as cortical tubers)1. Most 
individuals with TSC also develop epilepsy, and 25–50% are diagnosed 
with autism spectrum disorders. Although it has been proposed that 
the cortical tubers cause seizures and cognitive deficits, increasing 
evidence suggests that there is a poor correlation between cortical 
tubers and the incidence of epilepsy or autism in individuals with 
TSC2. Furthermore, animal models of TSC have increased suscep-
tibility to seizures in the absence of cortical tubers, supporting the 
notion that tubers are not responsible for epilepsy. Thus, other mecha-
nisms, such as miswiring of neuronal connections, may contribute 
to the pathogenesis of epilepsy, autism and intellectual disabilities in 
individuals with TSC.
TSC is caused by mutations in either of two genes, TSC1 or TSC2, 
whose protein products form a complex that is important in the phos-
phatidylinositol 3-kinase (PI3K)-Akt-mTOR pathway. Binding of a 
growth factor such as insulin to its cell surface receptor leads to activa-
tion of PI3K, which in turn activates the Akt kinase. Phosphorylation 
of TSC2 by Akt releases the inhibitory effect of the TSC1/TSC2 com-
plex on the Ras family GTPase Rheb3,4. Rheb and its downstream 
effector mTOR are master regulators of cell growth. When Rheb 
is activated, the protein synthesis machinery is turned on, most 
likely via mTOR, and cell growth programs are initiated. Therefore, 
the TSC1/TSC2 complex keeps cell size in check by inhibiting 
mTOR-mediated mRNA translation. Cells with insufficient TSC1 or 
TSC2 function grow beyond their normal size and form hamartomas, 
but the pathophysiology of the neurological symptoms in individuals 
with TSC remains poorly understood.
The establishment of neural circuits in vivo requires a precise inter-
action between extending axons and guidance cues in their environ-
ment. One of the best-characterized axon pathways in the CNS is 
the projection of retinal ganglion cells (RGCs) from the eye to their 
targets in the brain. Many proteins, such as neurotrophins, sema-
phorins, slits and ephrins, regulate retinal axon pathfinding and topo-
graphic mapping in target regions, such as the dorsal lateral geniculate 
nucleus (dLGN)5. Interactions between EphA receptors and ephrin-A 
ligands expressed in gradients in retinal neurons and across the dLGN 
are important for initial topographic map formation in the dLGN6. 
Spontaneous retinal activity then contributes to map refinement 
during postnatal stages7–9.
Binding of ephrin ligands triggers Eph receptor clustering, autophos-
phorylation and downstream signaling cascades that cause cytoskeletal 
rearrangements and changes in cell adhesion10. Through these mecha-
nisms, Eph receptors control axon turning, retraction and branching. 
Local regulation of protein synthesis and degradation in the axon 
also contributes to the rapid changes in growth cone dynamics that 
occur during axonal navigation11–15. Both repulsive and attractive cues 
can alter local protein translation in an mTOR-dependent manner, 
suggesting that guidance cues might affect axon growth and navigation 
at least in part by modulating mTOR activity14,16.
We found a new role for Tsc1/Tsc2 in axon guidance using mouse 
models of TSC. Components of the Tsc-mTOR pathway were 
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highly expressed in developing RGC axons, and Tsc2+/− mice, which 
have elevated mTOR activity in RGCs, developed aberrant retino-
geniculate projections. Consistent with this phenotype, in vitro 
Tsc2+/− RGCs were less sensitive to the repulsive effects of ephrin-A. 
Furthermore, EphA receptor signaling inhibited the mTOR pathway 
and reduced local protein synthesis in neurons. Our findings reveal 
a new mode of regulation of the Tsc-mTOR pathway by cell surface 
receptor tyrosine kinases through the ERK1/2 kinases and shed light 
on the mechanism by which EphA receptors control mTOR activity 
and growth cone dynamics.
RESULTS
Increased retinal mTOR activity in Tsc2+/− mice
We recently found that components of the Tsc-mTOR pathway are 
preferentially localized in the axons of embryonic hippocampal neu-
rons and that homozygous Tsc1 inactivation causes the formation of 
multiple axons17. Given that homozygous Tsc2 knockout results in 
embryonic lethality18 and that TSC is an autosomal dominant disease 
in which most cells in the brains of patients are probably heterozygous 
for TSC1 or TSC2 mutations, we investigated whether Tsc2 haploinsuf-
ficiency might also lead to a multi-axon phenotype. Double-labeling 
for the axonal marker Tau1 and the somato-dendritic marker MAP2 
revealed similar numbers of neurons with multiple axons in cultures 
of embryonic day 16 (E16) Tsc2+/− and wild-type cortical neurons 
(Supplementary Fig. 1), suggesting that Tsc2 haploinsufficiency may 
cause more subtle axonal abnormalities. Immunofluorescence stain-
ing of purified RGCs from the early postnatal retina confirmed that, 
similar to hippocampal neurons17, wild-type RGCs had higher axonal 
than dendritic levels of Tsc2 that was phosphorylated at the inhibitory 
Thr1462 site, total Rheb and active S6K1 (phosphorylated at Thr389) 
(Supplementary Fig. 2). This indicates that the Tsc2-Rheb-mTOR 
pathway is preferentially activated in the axonal compartment of dif-
ferent types of neurons, including RGCs. We therefore examined axon 
guidance and connectivity in Tsc2+/− mice, focusing on the developing 
retinogeniculate projection as a model system.
We first analyzed mTOR activity in the Tsc2-deficient retina. 
To facilitate analysis of RGCs, we stained retinal sections from 
postnatal day 23 (P23) mice for BIII-tubulin or the RGC markers 
Brn3a and Brn3b, in combination with phospho-S6 (Ser235/236), 
a reliable marker for mTOR activity (Fig. 1 and Supplementary Fig. 3). 
The percentage of Brn3a- or Brn3b-positive RGCs that were also 
positive for phospho-S6 was significantly higher in Tsc2+/− mice 
than in wild-type littermates (P < 0.01 and P < 0.05, respectively, 
by Mann-Whitney test). Quantification of phospho-S6 fluorescence 
intensity also revealed significantly higher phospho-S6 levels in Tsc2+/− 
than wild-type RGCs (P < 0.0001, by unpaired t test; Fig. 1d). Thus, 
RGCs with heterozygous Tsc2 inactivation have elevated mTOR 
signaling in vivo.
Abnormal retinogeniculate projections in Tsc2+/− mice
To determine whether Tsc2+/− mice have axon guidance defects, we 
labeled RGCs and their axonal projections with the anterograde tracer 
cholera toxin B (CTB). We injected one eye with CTB-594 (red) and 
the other with CTB-488 (green) at P14 and visualized the binocular 
retinogeniculate projections in dLGN sections at P16 (Fig. 2a,b and 
Supplementary Fig. 4). We noted that Tsc2+/− dLGNs occasionally had 
more than one ipsilateral patch (Fig. 2c), a defect that is similar to 
that described in ephrin-A2 and ephrin-A5 double-knockout mice7. 
Analysis of ipsilateral and contralateral projections19,20 revealed a 
small, but significant, increase in the percentage of the dLGN occupied 
by projections from the ipsilateral eye in Tsc2+/− mice compared with 
wild-type littermates (P < 0.05, by t test; Fig. 2d). In contrast, similar 
portions of the Tsc2+/− and wild-type dLGN were occupied by 
 contralateral projections or received overlapping inputs (Fig. 2e,f). 
Using a line-scan technique to calculate the mean pixel intensity along 
the dorsal-medial to ventral-lateral axes of the dLGN21, we found that 
the ipsilateral projections were shifted toward the ventral-lateral region 
in Tsc2+/− mice (Fig. 2g), similar to what was reported for ephrin-A 
knockout mice21.
The topography of RGC projections to the dLGN is regulated 
by the opposing gradients of EphA receptors expressed on RGC 
axons and ephrin-A ligands expressed on target cells6,22. Thus, the 
retinogeniculate topographic mapping defects in the Tsc2+/− mice 
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Figure 1 Increased mTOR activity in Tsc2+/− 
retina in vivo. (a) Flat mount (first and third row) 
or horizontal sections (second and fourth row) of 
retinas of Tsc2+/− mice and wild-type littermates 
on postnatal day 23 (P23) were stained with 
antibodies to phospho-S6 (Ser235/236, green) 
and Brn3a (red). Blue represents nuclear DAPI 
staining. Arrows denote double-labeled RGCs, 
and asterisks indicate phospho-S6–positive, 
Brn3a-negative cells. Scale bars represent 25 Mm  
in flat mounts and 50 Mm in cross-sections. 
(b) Flat mount retinas of Tsc2+/− mice and 
wild-type littermates (P23) were stained with 
antibodies to phospho-S6 (Ser235/236, green) 
and Brn3b (red). Arrows denote phospho-S6 
and Brn3b double-labeled RGCs. Scale bar 
represents 20 Mm. (c) Quantification of the 
phospho-S6–positive RGCs as shown in a and b. 
In both Brn3a- and Brn3b-positive populations, 
the numbers of phospho-S6–positive RGCs were 
significantly increased in Tsc2+/− mice compared 
with wild-type littermates (** P < 0.01  
and * P < 0.05 by Mann-Whitney tests).  
(d) Quantification of phospho-S6 (Ser235/236) fluorescence intensity as shown in a and b from Tsc2+/− versus wild-type (WT) mouse retinas. There was 
a significant increase in phospho-S6 fluorescence intensity in Tsc2+/− RGCs versus wild-type cells. Data are expressed as mean o s.e.m. (wild type,  


























! "LI!!NATURE NEUROSCIENCE VOLUME 13 | NUMBER 2 | FEBRUARY 2010 165
A R T I C L E S
ephrin-A–dependent growth cone repulsion or axon pruning. To 
distinguish between these two possibilities, we injected eyes with CTB 
at P4, before the onset of pruning and map refinement7. We found 
that the dLGN area occupied by ipsilateral projections was larger 
in Tsc2+/– mice than in wild-type mice (P = 0.0017 by ANOVA, 
n = 12 wild-type and 12 Tsc2+/− mice). Although we cannot completely 
rule out a contribution of pruning or crossing defects, these results 
indicate that the RGC projections to the dLGN are already aberrantly 
exuberant before pruning begins.
Because the ventral-lateral shift and the exuberance of the ipsilateral 
retinogeniculate projections in Tsc2+/− mice resemble the defects 
observed in ephrin-A–deficient mice21, we examined the topography 
of the RGC termination zones in the dLGN. We selectively labeled 
subsets of RGC axons with focal DiI-crystal placement in the ventral-
temporal quarter of the retina. Single termination zones restricted to 
the dorsal-medial end of the dLGN were observed in wild-type mice, 
as expected (Fig. 3a). In contrast, the termination zones in Tsc2+/−  
littermates showed a ventral-lateral shift and sometimes had more than 
one distinct termination zone (Fig. 3b). Quantification of the RGC ter-
mination zones along the dorsal-medial to ventral-lateral axis of the 
dLGN revealed a significantly larger extension of the Tsc2+/− RGC projec-
tions along the dorsal-medial to ventral-lateral axis compared with con-
trols (P < 0.01, by t test; Fig. 3c). Overall, the mapping defects observed 
in the Tsc2+/− ventral-temporal projections 
mimic those observed in ephrin-A knockout 
mice, suggesting that EphA receptor signaling 
is attenuated in Tsc2-deficient RGCs.
Loss of Tsc2 inhibits ephrin-induced growth cone collapse
After confirming that Tsc2 protein expression is reduced in Tsc2+/− whole 
retina lysates and isolated cortical neurons (Supplementary Fig. 4), we 
used Tsc2+/− RGCs to examine the sensitivity of their growth cones to 
ephrin-induced collapse23. Ephrin-A1 stimulation caused the collapse 
of 70–80% of wild-type RGC growth cones, but only 35–40% of Tsc2+/− 
growth cones (Fig. 4a,b). Wild-type and Tsc2+/− growth cones collapsed 
similarly in response to l-A-lysophosphatidic acid (LPA), however, indi-
cating that Tsc2 deficiency specifically impairs EphA receptor–mediated 
collapse (Fig. 4b). The decreased sensitivity of Tsc2+/− RGCs to ephrin-A 
is consistent with the aberrant pattern of retinogeniculate projections 
observed in vivo.
To verify that the decreased sensitivity of Tsc2-deficient growth 
cones to ephrin-A1 was not a result of lower EphA expression or 
signaling, we used a lentiviral shRNA17,24 to knockdown Tsc2 in 
cultured neurons. Tsc2 downregulation did not detectably affect 
EphA4, ephrin-A2 and ephrin-A5 protein levels (Supplementary 
Fig. 5). Furthermore, cell surface EphA4 level was not significantly 
affected in Tsc2 knockdown neurons, as revealed by the cell surface 
biotinylation assay (P > 0.05; Supplementary Fig. 5). Because 
ephrins induce Eph receptor clustering, which regulates signaling, 
we also verified that the density of EphA clusters was not altered 





































































































Figure 2 Tsc2+/− mice have defects in ipsilateral 
retinogeniculate projections. (a,b) A series of 
coronal sections from the anterior (top) to the 
posterior (bottom) showing retinogeniculate 
projections into dLGN in P16 Tsc2+/+ (a) and 
Tsc2+/− (b) mice. Alexa594 (red)- and Alexa488 
(green)-conjugated CTB were injected into the left 
and right eyes, respectively. D, dorsal; L, lateral. 
Dashed lines represent the borders of dLGN in 
sections displaying the ipsilateral projections. 
Scale bar represents 100 Mm. (c) In some Tsc2+/− 
mice, ipsilateral projection formed multiple 
patches rather than a single central patch. Axons 
from the ipsilateral eye are in green on top and 
red at the bottom. Scale bar represents 100 Mm. 
(d) Multi-threshold analysis of the percentage 
of ipsilateral projections in dLGN in wild-type 
versus Tsc2+/− littermates at P16. Tsc2+/− mice 
had larger ipsilateral territories than wild-type 
littermates, regardless of threshold. Data are 
expressed as mean o s.e.m. (n = 6 mice for each 
genotype, * P < 0.05 by t test). (e) Quantification 
of the percentage of contralateral projections 
in dLGN. No significant difference existed at 
any threshold between wild-type and Tsc2+/− 
littermates (P > 0.05 by t test). (f) Quantification 
of dLGN receiving contra-ipsi overlapping 
projections. No significant difference existed 
at any threshold between wild-type and Tsc2+/− 
littermates (P > 0.05 by t test). (g) The center of 
the ipsilateral projection in the dLGN was shifted 
ventrally and laterally in Tsc2+/− mice. We used 
the line-scan technique to calculate the mean 
pixel intensity along the dorsomedial (DM, 0%) to 
ventrolateral (VL, 100%) axes in 10 wild-type and 
11 Tsc2+/− littermates. Error bars represent s.e.m. 
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neurons (Supplementary Fig. 6). Thus, the effects of Tsc2 deficiency 
on the retinogeniculate projection in vivo and ephrin-A responsive-
ness of RGCs in vitro were not the results of aberrant ephrin-A/EphA 
expression, localization or clustering.
Because Tsc2 is a GTPase-activating protein (GAP) that inhibits 
mTOR by inactivating the small GTPase Rheb, we also investigated 
the role of Rheb in growth cone collapse. We used lentiviral vectors to 
express the constitutively active RhebS16H mutant, which is insensi-
tive to Tsc2, and wild-type Rheb, which was also substantially activated 
when overexpressed (Fig. 4c). Increased mTOR signaling was verified by 
measuring the phosphorylation of endogenous S6K1 and S6 in HEK293 
cells infected with the Rheb lentiviruses (Supplementary Fig. 7). 
Ephrin-A1 induced significant collapse in growth cones expressing 
wild-type, but not constitutively active, RhebS16H (P < 0.05 by t test). 
However, the collapse was reduced in neurons expressing wild-type 
Rheb or RhebS16H as compared with control neurons expressing only 
GFP (Fig. 4d). Therefore, similar to Tsc2 deficiency, Rheb hyperactiva-











































Figure 3 Tsc2+/− mice have defects in topographic mapping of contralateral projections in dLGN. (a) Representative series of fluorescent micrographs 
showing termination territories in contralateral dLGN from DiI-labeled ventro-temporal RGCs of Tsc2+/+ versus Tsc2+/− littermates at P19. Anterior is to 
the left and posterior to the right in each series of sections. Dashed lines represent the borders of dLGN. Arrows indicate DiI-labeled RGC termination 
zones. Insets represent tracings of the flat-mounted retina and injection site for each mouse. N, nasal; OT, optic tract; T, temporal; V, ventral.  
(b) Schematic drawings and colored dots show the position and area of DiI-labeled termination in each corresponding dLGN section from wild-type (red) 
and Tsc2+/− (green) littermates. In Tsc2+/− mice, the lower border of the termination extended erroneously into the area that is innervated by the ventral-
nasal RGCs in wild-type mice8. Scale bar represents 100 Mm. (c) Quantification of the percentages of dorsomedial to ventrolateral extension to length of 
dLGN along the same axis. Data are represented as mean o s.e.m. (19.1 o 2.1% in wild type, n = 4 mice; 50.3% o 9.7% in Tsc2+/− littermates, n = 6 
mice; ** P < 0.01 by t test).
Figure 4 Tsc2 deficiency and hyperactive Rheb inhibit ephrin-A–induced 
growth cone collapse. Purified RGCs from Tsc2+/− and wild-type 
littermates at P8 were stimulated with LPA (1 MM) or pre-clustered 
ephrin-A1–Fc or Fc (control) proteins (5 Mg ml−1). Growth cone  
collapse was determined by phalloidin staining. (a) Representative 
micrographs showing staining with rhodamine-phalloidin (red) and 
antibody to Tuj1 (green) of RGCs with intact versus collapsed growth 
cone. Scale bar represents 10 Mm. (b) Quantification of the percentage 
of RGCs with collapsed growth cone (GC). Data represent mean o s.e.m. 
Ephrin-A1–Fc stimulated collapse was markedly reduced in Tsc2+/− 
compared with wild-type RGCs (*** P < 0.001 by t test). There  
was no significant difference in LPA-treated growth cones from  
the two genotypes (P = 0.062 by unpaired t test). (c) The lentiviral  
construct was used to overexpress either wild-type Rheb (wtRHEB)  
or a constitutively active mutant (caRHEB, S16H), or GFP alone (GFP)  
as the control in Tsc2+/+ cells. Western analyses verified higher levels  
of Rheb, phospho-S6K1 (Thr389) and phospho-S6 (Ser235/6) in  
wtRHEB- and caRHEB-infected hippocampal neurons than those in  
GFP-infected or uninfected (NI) neurons, in either 2% (vol/vol) B27 
medium or B27-lacking medium for 16 h. Full-length gels are presented  
in Supplementary Figure 13. (d) Quantification of the percentage of  
growth cone collapse in purified RGC cultures infected with wtRHEB, 
caRHEB or GFP lentivirus. Results represent mean o s.e.m. from three 
independent experiments. RGCs with overexpression of wtRHEB or  
caRHEB had significantly less collapse than GFP-expressing RGCs (by  
t test, ** P < 0.01 comparing GFP infected cells in Fc versus ephrin-A1 stimulation; * P < 0.05 comparing wtRHEB-infected cells in Fc versus ephrin-A1 
stimulation; * P < 0.02 comparing ephrin-A1 stimulations between GFP- and wtRHEB-infected, or GFP- and caRHEB-infected, neurons; ns, not significant 
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Ephrin-As depress ERK and mTOR activities in neurons
We next examined whether there is crosstalk between EphA signaling 
and the mTOR pathway in neurons. Stimulation with ephrin-A1 led 
to EphA phosphorylation, which was detectable by 2 min and peaked 
at 30 min post-stimulation (Fig. 5a). We also observed an inverse 
correlation between EphA activation and ERK1/2 phosphorylation/
activation, consistent with previous findings in non-neuronal cells25. 
Ephrin-A1–treated neurons also had rapid dephosphorylation of 
S6K1 by 2–5 min post-stimulation and a delayed decrease in phospho-
S6 after ~15 min of stimulation (Fig. 5a,b). 4E-BP1, another effec-
tor of mTOR, was also dephosphorylated on ephrin-A1 stimulation. 
Furthermore, ephrin-A1 inhibited phosphorylation of ERK1/2, S6K1 
and S6 in a dose-dependent manner (Fig. 5c). Stimulation of cortical 
neurons with ephrin-A5, the predominant ephrin-A in the dLGN, also 
decreased ERK1/2, S6K1 and S6 phosphorylation, but with a slower 
time course (Fig. 5d,e). The levels of activated Akt (phosphorylated 
at Ser473) and TSC2 phosphorylated at Thr1462, a site phosphor-
ylated by Akt, remained constant throughout the period of ephrin 
stimulation. Thus, activation EphA receptor signaling inhibits both 
ERK1/2 and the mTOR pathway in neurons, the latter being inhibited 
independently of the upstream mTOR regulator Akt.
Ephrin-As inhibit protein synthesis in isolated neurites
Inhibition of mTOR activity by ephrin-As would be expected to 
repress protein synthesis in neurites and growth cones. We used 
the modified Boyden chamber system to harvest neurite-enriched 
lysates from neuronal cultures and measure metabolic incorporation 
of 35S-labeled amino acids into newly synthesized proteins (Fig. 6a). 
Ephrin-A1 and the mTOR inhibitor rapamycin both caused a similar 
25–35% reduction in protein synthesis, whereas translation inhibi-
tors such as UO126 and anisomycin almost completely blocked 35S 
incorporation (Fig. 6b,c). Thus, mTOR inhibition by rapamycin 
or ephrin-A1 appears to substantially reduce protein synthesis 
in neurites.
Local translation and degradation of B-actin and proteins that reg-
ulate the actin cytoskeleton are important for controlling cytoskeletal 
dynamics in axons and growth cones13–16. To monitor local transla-
tion in ephrin-A1–stimulated neurons, we used the dGFPmyr-bACT 
3` UTR construct, which encodes a destabilized and myristoylated GFP 
from a transcript fused to the 3` UTR of B-actin26 (Supplementary 
Fig. 8). This 3` UTR contains a sequence for localization to neuronal 
processes. In fluorescence recovery after photo-bleaching experiments, 
we photo-bleached axonal terminal portions, including the growth 
cones of transfected neurons, and monitored signal recovery over a 
period of ~20 min. In general, this time scale is not long enough for 
transport or diffusion of myristoylated dGFP protein from the soma to 
the growth cone27,28. The dGFPmyr-bACT 3` UTR fluorescence signal 
recovered rapidly after bleaching in control neurons, whereas fluores-
cence recovery was minimal for the co-transfected control d2-mCherry 
(data not shown). dGFP fluorescence recovery in axons pre-treated 
with the translation inhibitor anisomycin (100 MM) was markedly 
delayed and repressed, as expected (Fig. 6d–f and Supplementary 
Fig. 8). Notably, fluorescence recovery in the presence of ephrin- 
A1–Fc was significantly reduced compared with Fc control (P < 0.05 
by two-way ANOVA). These findings suggest that ephrin-A1 stimula-
tion inhibits fast and localized translation of B-actin and other mRNAs 
kD
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Figure 5 Inactivation of ERK1/2 and  
mTOR pathway in ephrin stimulated neurons. 
(a) Tsc2+/+ cortical neurons maintained in 
culture for 7 d were stimulated with either 
pre-clustered ephrin-A1–Fc or Fc as a control. 
Western analyses of neurons stimulated with  
5 Mg ml−1 proteins for the indicated minutes 
are shown. Total EphA4, ERK1/2, S6K1, S6 
and tubulin were used as loading controls.  
(b) Quantitative analysis of phospho-protein 
levels over the stimulation course as in a. 
Significant reduction in phosphorylation  
levels was found by t test at each time point 
versus 0 min (** P < 0.01 comparing phospho-
S6K1 (Thr389) at 2 min and *** P < 0.001 
at 5, 15, 30 or 60 min; # P < 0.05 comparing 
phospho-ERK1/2 at 15 min and ## P < 0.01  
at 30 or 60 min). (c) Western analyses of 
cortical neurons stimulated for 30 min with 
ephrin-A1 at ascending concentrations  
(0.1, 1, 5, 10 and 20 Mg ml−1). Total ERK1/2 
and tubulin were used as loading controls.  
(d) Western analyses of Tsc2+/+ cortical  
neurons grown in culture for 12 d and 
stimulated with either pre-clustered Fc  
(as the control) for 60 min or ephrin-A5–Fc  
for the indicated minutes. Total mTOR, S6  
and tubulin were used as loading controls.  
(e) Quantification of the phosphorylation  
levels of mTOR, S6 and ERK1/2 in Fc  
versus ephrin-A5-Fc (5 Mg ml−1) stimulations.  
A significant reduction in phosphorylation 
levels was found by t test comparing  
ephrin-A5 at each time point versus  
Fc stimulation (* P < 0.05 comparing phospho-S6 at 30 min and ** P < 0.01 at 60 min; # P < 0.05 comparing phospho-mTOR at 60min;  
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in the growth cone. Nevertheless, we did not detect substantial effects 
of anisomycin or rapamycin on ephrin-A1–induced growth cone 
collapse (data not shown), as previously reported29. This suggests 
that the inhibition of mTOR activity and local translation induced 
by ephrin stimulation is already sufficient for maximal growth 
cone collapse.
Guidance cues differentially modulate Tsc2 activity
Consistent with its inhibitory effects on ephrin-dependent growth 
cone collapse, Tsc2 knockdown abolished ephrin-A1–dependent down-
regulation of S6K1 and S6 phosphorylation in neurons (Fig. 7a,b). 
The levels of phospho-S6K1 and phospho-S6 remained unchanged 
over a 60-min time course of ephrin stimulation, excluding the 
possibility of a delayed dephosphorylation (Fig. 7c). Cre-mediated 
inactivation of the Tsc1/Tsc2 complex in cortical neurons isolated from 
Tsc1loxP/loxP or Tsc2loxP/loxP mice also prevented ephrin-A–dependent S6 
dephosphorylation (Supplementary Fig. 9). Furthermore, ephrin-A1 
stimulation decreased S6K1 and S6 phosphorylation in wild-type, but 
not Tsc2−/−, mouse embryonic fibroblasts (Supplementary Fig. 10), 
indicating that EphA signaling can also regulate the mTOR pathway in 
non-neuronal cells. These results suggest that Tsc2 is both necessary and 
sufficient for the negative regulation of mTOR activity by ephrin-As, 
probably via a mechanism that does not involve Tsc2 phosphorylation 
by Akt at Thr1462 (see above). Notably, ERK1/2 inactivation by 
ephrin-A1 still occurred in Tsc2 knockdown neurons, even though 
baseline ERK1/2 phosphorylation was lower than in control neurons 
(Fig. 7a,b). Thus, ERK1/2 might be responsible for EphA-dependent 
Tsc2 activation.
Tsc2 activity can be inhibited not only by Akt-dependent phos-
phorylation at Thr1462 and Ser939, but also by ERK-dependent 
phosphorylation at Ser664 (refs. 4,30). Brain-derived neurotrophic 
factor (BDNF) stimulation markedly increased Akt and ERK1/2 phos-
phorylation in cultured neurons, whereas ephrin-A1–Fc significantly 
suppressed ERK1/2, but not Akt, phosphorylation (P < 0.05, t-test; 
Fig. 8a). We therefore used phospho-specific antibodies to assess 
the modulation of Tsc2 by Akt and ERK1/2 in neurons stimulated 
with BDNF or ephrin-A1. As expected, S6K1 phosphorylation was 
upregulated by BDNF and downregulated by ephrin-A1 stimulation 
(Fig. 8a). BDNF also increased Tsc2 phosphorylation of both Thr1462 
and Ser664 about twofold compared with control-treated neurons 
(Fig. 8a,b). In contrast, Tsc2 Ser664 phosphorylation was approxi-
mately 35% lower in ephrin-A1-stimulated cells than in control-
treated cells. These results suggest that, in cultured neurons, BDNF 
increases Tsc2 phosphorylation through activation of both Akt and 
Figure 6 Ephrin inhibits axonal protein 
synthesis and the local translation of a beta-
actin reporter in growth cones. (a) Schematic 
representation of the experimental design using 
[35S]-labeling and collection of axon-enriched 
lysates using Boyden transwells (see Online 
Methods). (b) Cell bodies of rat hippocampal 
neurons grown in Boyden transwells were 
removed and the neurites in the lower chamber 
were stimulated immediately with pre-clustered 
Fc, ephrin-A1–Fc (5 Mg ml−1), UO126  
(20 MM), rapamycin (20 nM) or anisomycin  
(40 MM) for 30 min. Quantification of the  
[35S] incorporation (cpm Mg−1) in trichloroacetic 
acid (TCA)-precipitated lysate showed that 
ephrin-A1 inhibited de novo protein synthesis 
as compared with Fc, but to a lower extent 
than UO126, rapamycin or anisomycin. Results 
represent mean o s.e.m. from three independent 
experiments (** P < 0.01, *** P < 0.001 and 
**** P < 0.0001 by t tests). (c) A representative 
[35S] autoradiograph showing a reduction 
in the amount of newly synthesized proteins 
from axons treated with ephrin-A1, UO126, 
rapamycin or anisomycin compared with control 
Fc–treated axons. (d) Hippocampal neurons 
were transfected with dGFPmyr-bACT 3` UTR and 
the dashed lines represent regions of bleaching. 
Representative images show the fluorescence 
recovery after photobleaching in terminal axons 
of transfected neurons over a period of 20 min  
in the presence of ephrin-A1–Fc or Fc as 
control. Arrows indicate axonal growth cones. 
Scale bar represents 20 Mm. (e) Quantification 
of GFP fluorescence intensity pre- and 
post-bleaching in ephrin-A1–Fc versus Fc 
treatments. Data at each time point represent 
average percentage of pre-bleach levels o s.e.m. 
(n = 3 for Fc and n = 6 for ephrin-A1–Fc). 
Significant difference in signal recovery was 
assessed by two-way ANOVA when comparing 
ephrinA1 versus Fc treatments at each time point post-bleaching (* P < 0.05, ** P < 0.01 and *** P < 0.001 at 7~19 min). (f) Quantification of GFP 
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ERK, which synergistically inhibit Tsc2 GAP function toward Rheb, 
whereas ephrin-A1 selectively decreases phosphorylation of Tsc2 
at the ERK site. Thus, the Tsc-mTOR pathway can be positively or 
negatively regulated by distinct axon guidance cues.
We then examined whether ephrin-A stimulation can regulate Tsc-
mTOR signaling locally in the axon. We detected high phospho-Tsc2 
(S664) immunofluorescence in growth cones and filopodia 
(Supplementary Fig. 11). On ephrin-A1 stimulation, the signal 
diminished rapidly from the growth cone and axon tips. At 5 min 
post stimulation, when the majority of growth cones (83%) have not 
yet collapsed, we observed a significant reduction of phospho-Tsc2 















































































































































































































































Figure 8 Regulation of TSC2 (Ser664) 
phosphorylation by ephrin-A1 is involved in 
growth cone dynamics. (a) Tsc2+/+ cortical 
neurons were maintained in culture for 12 d 
and were stimulated as indicated for 30 min. 
Phospho-TSC2 (Ser664) or phospho-TSC2 
(Thr1462), along with total TSC2, were probed 
on the same blots and total Akt1 was used as the 
loading control. Full-length gels are presented 
in Supplementary Figure 14. (b) The intensities 
of phospho-TSC2 (Ser664) and phospho-
TSC2 (Thr1462) were normalized to total 
TSC2. Data are expressed as the percentage of 
vehicle-treated intensity o s.e.m. (* P < 0.05 
comparing p-TSC2 (Ser664) in ephrin-A1 versus 
vehicle or BDNF versus vehicle; ** P < 0.01 
comparing phospho-TSC2 (Thr1462) in BDNF 
versus vehicle treatment, t test). (c) Purified 
RGC cultures from P7 rats were stimulated 
as indicated and then stained with antibody 
to phospho-TSC2 (Ser664) and rhodamine-
phalloidin. Phospho-TSC2 (Ser664) staining 
was converted to pseudo-colored spectrum 
display to distinguish intensity change. Scale 
bar represents 10 Mm. (d) Quantification of pixel 
intensity of phospho-TSC2 (Ser664) labeling in 
RGC growth cones. Data represent mean o s.e.m. 
(n = 4–10 growth cones, * P < 0.05, ** P < 0.01 
and ns = not significant (P = 0.156) by unpaired t test). (e) Transfection of neurons with phospho-mimic mutant of TSC2 partially blocked growth cone 
collapse. Rat hippocampal neurons transfected with wild-type TSC2, mutant TSC2 (S664D/S540D) or empty control plasmids were stimulated with Fc 
or ephrin-A1–Fc for 30 min. Growth cone collapse was determined by phalloidin staining. Data represent mean percentage collapse o s.e.m. from three 
independent experiments with duplicates in each experiment (* P < 0.05, ** P < 0.01 and ns = not significant (P = 0.333) by unpaired t test).
Figure 7 Tsc2 is required for ephrin-A1–
stimulated mTOR inactivation. Tsc2+/+ cortical 
neurons were infected with lentivirus expressing 
shRNA specific for Tsc2 (T2sh1) or a firefly 
luciferase (GL3, control). Both uninfected and 
infected neurons were then stimulated with  
pre-clustered ephrin-A1–Fc versus Fc for 
30 min. (a) Representative western blots 
for indicated proteins. Downregulation of 
Tsc2 decreased Tsc1 levels and increased 
SAD-A/B levels, consistent with our previous 
findings17,24. There were no significant 
differences in EphA4 and EphA5 expression, 
ephrin-induced EphA tyrosine phosphorylation 
or in ephexin phosphorylation between Tsc2 
knockdown and control neurons (P > 0.2 by 
t test). Tsc2 knockdown abolished the ephrin-
A1–dependent downregulation of S6K1 and S6 
phosphorylation observed in control neurons. 
Inactivation of ERK1/2 by ephrin-A1 was still 
observed in the Tsc2 knockdown neurons, even 
though the baseline level of phospho-ERK1/2 
was lower in these neurons than in the controls. Total ERK1/2, S6 were used as loading controls. Full-length gels are presented in Supplementary  
Figure 14. (b) Quantification of the western blot analyses. Relative intensities for each protein were normalized according to the tubulin loading 
control and expressed as mean ratios of GL3 or T2sh1 to uninfected neurons in each independent experiment. Data represent mean o s.e.m. from 
four independent experiments (* P < 0.05, ** P < 0.01, *** P < 0.001 and ns = not significant (P > 0.4) by t test). (c) T2sh1-infected neurons were 
stimulated with pre-clustered ephrin-A1–Fc or control Fc proteins for the indicated time periods. Phospho-S6K1 and phospho-S6 remained unchanged 
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Fig. 8c,d). Phospho-S6K1 immunofluorescence showed a similar 
reduction after ephrin-A1 treatment (Supplementary Fig. 11). 
Ephrin-A1 stimulation for 15 min led to complete growth cone col-
lapse, coincident with only a faint residual phospho-Tsc2 (S664) and 
phospho-S6K (T389) signal in the axon tips. Thus, ephrin-A1 induces 
fast dephosphorylation of Tsc2 on Ser664 and S6K1 on Thr389 in the 
growth cone, consistent with the timing of inhibition of local transla-
tion in growth cones measured with the B-actin reporter.
To confirm that the rapid change in Tsc2 phosphorylation in the 
growth cone is involved in ephrin-dependent growth cone collapse, 
we transfected neurons with wild-type Tsc2 or the phospho-mimic 
S540D/S664D mutant30. We observed a partial blockade of ephrin-
A1–induced growth cone collapse by the phospho-mimic Tsc2 
mutant, but not by wild-type Tsc2 (Fig. 8e). This indicates that ERK 
regulates Tsc2 activity in the cellular machinery that controls growth 
cone dynamics in response to ephrin stimulation.
DISCUSSION
We found that the Tsc1/Tsc2 complex was required for ephrin-A–
induced growth cone collapse and determined a mechanism by which 
ephrins can regulate the Tsc-mTOR pathway in axons. We also found 
that Tsc2-deficient RGCs projected aberrantly to the dLGN, indi-
cating that the Tsc-mTOR pathway is important for Eph-mediated 
axon guidance in vivo. Therefore, Tsc2-mediated regulation of mTOR 
is crucial for growth cone dynamics and proper axon pathfinding 
(Supplementary Fig. 12).
Eph receptors in neural development, plasticity and repair
The role of Eph receptors and ephrins in the CNS has been exten-
sively studied and a notable feature is the diversity of their functions10. 
The Eph receptors represent the largest family of receptor tyrosine 
kinases in the mammalian genome and regulate various signaling 
pathways through a number of downstream effectors, including gua-
nine nucleotide exchange factors (Ephexins, Kalirin, Intersectin and 
Tiam1), GTPase-activating proteins (p120RasGAP, A2-chimaerin and 
SPAR), tyrosine kinases (Src, Abl and Fak), phosphatases (LMW-PTP 
and Ship2) and adaptor proteins (Nck, Grb2, Grb4 and Crk)10. Here, 
we discovered a pathway in which Eph receptors regulate mTOR via 
ERK inhibition, which leads to Tsc2 activation. Eph forward signaling 
probably simultaneously modulates this and other signaling pathways 
to modify cytoskeletal dynamics in the growth cone. We found that 
ephrin-As inhibited mTOR activity in neurons, and it will be interesting 
to examine whether ephrins of the B class can also regulate mTOR.
Eph/ephrin signaling is important in the formation of not only 
retinal connections, but also other axonal projections, such as cortico-
spinal and thalamocortical connections and the corpus callosum. 
Our findings in the retinogeniculate connections may therefore have 
general relevance for the mapping of axonal connections in the devel-
oping CNS. Recently, the Eph system was also shown to be impor-
tant for radial column formation in the neocortex, implicating these 
molecules in neuropsychiatric disorders associated with abnormal 
columnar organization31. Whether TSC mouse models have abnormal 
columnar organization has not yet been investigated. Eph receptors 
and ephrins also persist in the adult brain, particularly in regions 
where neuronal circuits continue to be remodeled, such as the hippo-
campus32. The hippocampal long-term potentiation (LTP) and learn-
ing abnormalities reported in Tsc-deficient mouse models could be 
explained, at least in part, by the involvement of the Tsc-mTOR path-
way in Eph signaling33. Finally, multiple Eph receptors and ephrins 
are upregulated at sites of CNS injury, where they seem to hinder 
axon regeneration through their repulsive signaling34. In particular, 
EphA4 is emerging as an inhibitor of nerve regeneration, possibly by 
interacting with both ephrin-B2 in reactive astrocytes and ephrin-B3 
in myelin. Recently, mTOR activation by Pten or Tsc1 knockout was 
shown to promote the regenerative capacity of injured axons35. Our 
data suggest that one of the possible mechanisms by which mTOR acti-
vation could promote axon regeneration is by opposing Eph repulsive 
signaling. Further experiments involving genetic and chemical 
manipulations of Eph and mTOR signaling are needed to better 
delineate their interaction during axon regeneration.
The role of mTOR in axon guidance
We found that, on Eph activation, ERK activity was inhibited. This 
led to the activation of TSC2, which inhibited Rheb. Consistent with 
these findings, the loss of Tsc2 and overexpression of constitutively 
active Rheb decreased the responsiveness of growth cones to repul-
sive ephrin signals. To date, mTOR is the only known downstream 
target of Rheb. There are two distinct mTOR complexes: mTORC1, 
which mainly regulates the translational machinery, and mTORC2, 
which mainly regulates the actin cytoskeleton. mTORC1 is acutely 
sensitive to rapamycin, whereas mTORC2 is not, although mTORC2 
can be inhibited by long-term rapamycin treatment. Rheb can acti-
vate mTORC1 by disrupting the binding of the inhibitory protein 
FKBP38, but reportedly inhibits mTORC2 (ref. 36). Thus, the similar 
reduction in growth cone collapse by suppression of Tsc2 or over-
expression of Rheb strongly suggests that this phenotype is medi-
ated by mTORC1. Notably, previous studies have shown that growth 
cone collapse induced by semaphorins or Slit requires rapamycin- 
sensitive mTOR activity16,37, suggesting that either too much or too 
little mTORC1 activity may interfere with growth cone dynamics and 
result in aberrant axon guidance.
The mTOR pathway is a critical regulator of protein synthesis and 
we found that ephrin stimulation reduced protein synthesis in neu-
rons. However, mTOR might mediate additional functions down-
stream of Eph receptors, including transcription, ubiquitin-dependent 
proteolysis, autophagy, membrane trafficking, and microtubule and 
actin cytoskeleton dynamics. Additional experiments are needed to 
determine whether the role of mTOR in ephrin-dependent growth 
cone guidance involves regulation of protein synthesis or additional 
mechanisms, such as regulation of cytoskeletal dynamics.
Accumulating evidence suggests that the machineries for protein 
synthesis and degradation are both present and locally active in the 
growth cone and can be regulated by guidance cues11,38. Axon guid-
ance molecules such as netrin-1 and semaphorins can trigger protein 
synthesis in retinal growth cones isolated from their cell bodies16 and 
inhibition of mTOR has been shown to interfere with proper RGC 
axon pathfinding. Two recent studies have shown that B-actin mRNA 
is subject to local translation in the growth cone. In Xenopus, the 
growth cone turning activity of BDNF requires local protein synthesis 
and is abolished by inhibitors of mRNA translation15. Local BDNF 
exposure induces colocalization of B-actin mRNA with the asym-
metrically localized ZBP1 protein, resulting in asymmetric distribu-
tion of newly translated B-actin and growth cone turning. Similarly, 
netrin induces transport of Vg1RBP (the Xenopus homolog of ZBP1) 
into filopodia and increases B-actin translation13. This requires the 
3` UTR of the B-actin mRNA and mTOR activity. Our results suggest 
further molecular links between axon guidance cues and local mRNA 
translation in the axon, including the Tsc1/Tsc2 complex and Rheb. 
Furthermore, we found that ephrin-dependent growth cone collapse 
involves ERK inactivation and consequent Tsc2 activation, resulting 
in mTOR suppression. Therefore, the mTOR kinase can be used by 
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There are at least two mechanisms by which mTORC1 regulates the 
translational machinery: phosphorylation of S6K, which increases the 
translation of mRNA transcripts containing a tract of pyrimidine motif, 
and phosphorylation of the eIF4E-binding proteins, which relieves the 
inhibitory effect of 4EBP1 on cap-dependent translation initiation. The 
roles of S6K and 4EBP1 in axons are poorly characterized, although 
we recently found that activated S6K1 is preferentially localized in the 
growing axon when neurites are first developing17. Identification of 
the repertoire of mRNAs whose translation is regulated by the Tsc-
mTORC1 pathway in axons will provide important insights into the 
role of translational control in growth cone dynamics.
Pathogenesis of TSC disease
Although substantial progress has been made in identifying the 
molecular and cellular mechanisms underlying tuber formation in 
individuals with TSC, an important unresolved issue is what causes 
seizures and autistic features in these individuals2,39–41. Advances over 
the past few decades have suggested that dysregulation of axon growth 
and guidance is important in the pathogenesis of epilepsy, autism and 
intellectual disabilities. Deficient axonal growth has been associated 
with cerebral dysgenesis and intellectual disability42, whereas exces-
sive growth of neuronal processes has been associated with epilepsy43. 
The role of neuronal connectivity has also become apparent in autism. 
Magnetic resonance imaging studies have also demonstrated increased 
white-matter volume44 and aberrant white matter adjacent to brain 
regions implicated in social cognition in autistic individuals45, sug-
gesting that abnormal connections between brain regions involved 
in social functioning may contribute to impaired social cognition. It 
will be interesting to see if individuals with TSC and autism can be 
distinguished from those with TSC, but not autism, on the basis of 
abnormal connectivity in regions involved in social cognition.
Individuals affected by TSC carry heterozygous mutations in either 
the TSC1 or the TSC2 genes. Loss of heterozygosity (LOH) has been 
demonstrated in lesions such as cardiac rhabdomyomas, renal angio-
myolipomas and subependymal giant cell astrocytomas, but not in 
cortical tubers46. In animal models, acute inactivation of the Tsc1 gene 
in hippocampal slice cultures results in increased soma size, decreased 
spine density and increased spine length in pyramidal neurons47. 
Moreover, Tsc1+/− mice have deficits in hippocampal-dependent 
learning. They also spend less time with unfamiliar mice and are 
worse at nest building compared with wild-type littermates, two lines 
of evidence that suggest abnormal social behavior. However, analysis 
of adult Tsc1+/− brains failed to detect any changes in cell soma size, 
spine density or dendritic arborization48. Therefore, the neuro-
pathology associated with the cognitive and behavioral deficits remains 
 unclear. Our data indicate that Tsc2 haploinsufficiency causes defects 
in axonal connectivity. It will be interesting to investigate whether 
the abnormalities that we have detected in the projections of retinal 
neurons may also be present in other neuronal populations and may 
contribute to the neurobehavioral phenotype of TSC mouse models 
and individuals with TSC.
METHODS
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
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ONLINE METHODS
Antibodies, constructs and animals. Phospho-TSC2 (S664)30, EphA4, phospho- 
EphA49 and phospho-ephexin23 antibodies have been described previously. 
Antibodies to phospho-ERK1/2, total ERK1/2, phospho-TSC2 (T1462), Rheb, 
phospho-S6K1 (T389), total S6K1, phospho-S6 (S235/236), total S6, phospho- 
Akt (S473), phospho-4E-BP1 (T37/46), phospho-mTOR (S2481) (Cell 
Signaling), TSC2, EphA4, ephrin-A2, ephrin-A5, EphA5, Brn3b (H-18), (Santa 
Cruz), phospho-TSC2 (S664) (BioLegend), TSC1 (Zymed), TSC2 (Biosource), 
Tau1 (Chemicon), MAP2 (sigma), chimaerin1 (Abnova), Brn3a, SAD-A/B 
(Millipore), recombinant ephrin-A1–Fc, ephrin-A5–Fc (R&D systems) and 
BDNF (Biosource), and the chemicals PMA, U0126, rapamycin (Sigma) and 
anisomycin (Calbiochem) were obtained commercially.
The dGFPmyr-bACT 3` UTR and d2-mCherry constructs were generous gifts 
from J. Twiss (University of Delaware) and G Bassell (Emory University), respec-
tively. The lentiviral Tsc2 shRNA construct was custom made by Cellogenetics17. 
Tsc2+/− and Tsc2f/f mice were previously described18,50. All procedures were carried 
out in accordance with the Guide for the Humane Use and Care of Laboratory 
Animals and our study was approved by the Animal Care and Use Committee of 
Children’s Hospital Boston.
Site-directed mutagenesis. Total RNA was isolated from cultured rat cortical 
neurons with a Qiagen RNeasy kit according to the manufacturer’s instructions. 
Complementary DNA was then synthesized with Superscript II reverse tran-
scriptase. From the cDNA pool, rat Rheb was PCR amplified with the primer set 
5`-AAG GAA AAA AGC GGC CGC ACC ATG CCT CAG TCC AAG TCC CGG-3` 
(forward) and 5`-CGG GAT CCT CAC ATC ACC GAG CAC GAA GAC TTC 
CCT TG-3` (reverse). For packaging lentivirus, Rheb PCR product was further 
cloned into the pHAGE-CMV-IRES lentiviral vector at NotI/BamHI sites. Rheb 
S16H mutant was generated using a QuikChange II XL site-directed mutagenesis 
kit (Stratagene) with the primers 5`-CCA TCC TGG GCT ATC GGC ATG TGG 
GAA AGT CCT CAT-3` and 5`-ATG AGG ACT TTC CCA CAT GCC GAT AGC 
CCA GGA TGG-3`.
Lentivirus infection, neuronal culture and immunocytochemistry. Lentiviri 
were pseudo-typed in HEK293T cells that were co-transfected with packaging 
vectors (rev, tat, gag/pol, vsv-g) and each lentiviral construct. Transfection solu-
tions were replaced 6 h later with DMEM containing 1% FBS. Viral supernatants 
were collected twice at 48 and 60 h after transfection, filtered and frozen.
RGCs were prepared from P7 rat or P8 mouse pups according to the immuno-
panning method as described previously23. Cortical and hippocampal neurons 
were isolated from E18 rat or E16 mouse embryos. Briefly, cortex and hippocampi 
were dissected out and dissociated in papain for 5 min in HEPES-buffered Hank’s 
solution. Cells were grown on poly-d-lysine and mouse laminin–coated glass 
coverslips or only poly-d-lysine–treated plates/dishes in Neurobasal medium with 
B27 (Invitrogen). The day after plating, neurons were infected with lentivirus in 
the presence of 0.6 Mg ml−1 polybrene for 6 h. To overexpress Rheb, we infected 
the neurons twice at the second and third day after plating.
For immunocytochemistry, neurons were fixed with 4% paraformaldehyde 
(vol/vol)/4% (wt/vol) sucrose in phosphate-buffered saline (PBS) for 10 min. 
Fixed cells were permeabilized in 0.1% (vol/vol) Triton X-100 for 15 min and 
blocked in 4% (vol/vol) normal goat serum and 2% (wt/vol) BSA in PBS. 
Typically, neurons were incubated with the primary antibody at 4 °C overnight 
and fluorescent secondary antibody for 2 h at room temperature (22–25 °C). 
Images were captured using a Zeiss LSM5 confocal microscope system.
Nucleofection. E18 rat hippocampal and cortical neurons were transfected 
immediately after dissociation using Amaxa Nucleofector (Amaxa Biosystems) 
system and plated at 50,000 neurons per 13-mm2 coverslip. Neurons were used for 
growth cone collapse assay or live imaging 2 d after plating and transfection.
Ephrin-A1 stimulation and growth cone collapse assay. Ephrin-A1 stimulation 
and quantification of growth cone collapse was performed as described 
previously23. Briefly, to pre-aggregate proteins, recombinant ephrin-A1–Fc, 
ephrin-A5–Fc (R&D system) or human IgG Fc (Jackson Immunoresearch Labs) 
was incubated with goat antibody to human Fc (Jackson Immnoresearch Labs) 
at ratio of a 1:4.5. The volume was adjusted with HBSS to 5×. After shaking for 
45 min at room temperature, proteins were diluted in conditioned culture media 
and added to the neuronal cultures. Generally, cells were stimulated for 30 min 
before lysis or fixation unless otherwise specified. LPA-stimulated collapse was 
performed at 1 MM for 10 min before fixation. To visualize growth cone collapse, 
we stained fixed neurons with rhodamine-phalloidin (Cytoskeleton). Growth 
cones that had not collapsed were identified by the presence of lamellipodia and 
two or more filopodia. Collapsed growth cones were distinguishable from their 
noncollapsed counterparts by the presence of a collapsed bulb and having fewer 
than two filopodia at the leading edge. Counting of growth cone collapse was 
performed blind to genotype or treatment.
EphA receptor clustering study. Hippocampal neurons infected with GL3 against 
luciferase or TSC2 shRNA (T2sh1) lentivirus were treated with pre-aggregated 
ephrin-A1–Fc versus Fc (1–2 Mg ml−1) for 5 min at 37 °C. Neurons were fixed, 
washed, permeablized (0.1% Triton X-100) and stained with cy3-conjugated 
antibodies to human IgG Fc and Tau-1. EphA clusters were imaged with Leica 
LSM5 confocal system. EphA clusters/punta were counted blind to treatments.
CTB injection and DiI labeling. CTB labeling and analyses were performed as 
previously described20. Briefly, mouse pups at P14 were injected binocularly with 
fluorescence-labeled CTB subunit (Alexa 488 or Alexa 594, Molecular Probes) and 
allowed to recover for 48 h. Dissected brains were fixed in 4% paraformaldehyde 
for 48 h at 4 °C. Coronal sections (100 Mm) were imaged with a 10× objective. 
All of the image acquisition and analyses were performed blind to genotype. The 
same gains and image exposure times were used for each label in all specimens 
to limit variability caused by imaging procedures. Raw images of the dLGN were 
imported to Adobe Photoshop. The size of the ipsilateral, the contralateral and 
the degree of overlap were quantified with the multi-threshold protocol, which 
is designed to compare overlap across a range of signal-noise values in control 
versus mutant mice19,20.
To compare the distribution of the ipsilateral projection pattern, we employed 
a line-scan technique to calculate the mean pixel intensity of projection terminals 
in wild-type and Tsc2+/− mice along the long (dorsomedial to ventrolateral) axis. 
The location of the center of the ipsilateral projection was calculated with the 
dorsomedial border of the LGN set as 0% and the ventrolateral border as 100%.
To focally label RGCs in the ventro-temporal quarter of retina, we embedded a 
~1-mm3 DiI crystal (Molecular Probe) below the cornea-sclera border along the 
ventrotemporal dorsonasal orientation into the right eyeball. Mice were killed 
5 d later and intercardially perfused with 4% paraformaldehyde in PBS. The 
eyeballs were extracted and post-fixed in 4% paraformaldehyde for 1 h and the 
brains were post-fixed overnight. Retinal whole-mounts were dissected out 
to determine DiI labeling position and area. Brains corresponding to retinas 
that had comparable DiI labeling were further sectioned with a Leica cryostat 
and the contralaterally labeled dLGN serial sections were imaged with a Nikon 
fluorescence microscope with a 10× objective and mounted Hamamatsu ORCA-
ER camera. Further image processing was performed using Adobe Photoshop and 
the dorsomedial-ventrolateral extension of dLGN labeling was measured using 
ImageJ (US National Institutes of Health).
[35S] metabolic labeling of nascent proteins. De novo protein synthesis was 
quantified by measuring the incorporation of 35S-Met/Cys (Perkin Elmer) in 
TCA-precipitated proteins. Cortical neurons (12 d in vitro) in Boyden transwells 
were washed with and switched to Met/Cys/serum-free DMEM (Invitrogen) for 
30 min at 37 °C to deplete intracellular methionine and cysteine. Prior to stimula-
tion and/or 35S labeling, cell bodies were removed in the top chamber and further 
washed with equilibrated Met/Cys/serum-free DMEM. The bottom chamber was 
incubated with pre-clustered Fc or ephrin-A1–Fc (5 Mg ml−1) in the presence 
of 35S-Met/Cys (40 MCi ml−1) for 30 min or with UO126 (20 MM), rapamycin 
(20 nM) or anisomycin (40 MM) for 10 min before adding 35S-Met/Cys for another 
20 min. Axon-enriched lysates were harvested in 100 Ml of RIPA buffer (with pro-
tease inhibitors and phosphotase inhibitors). We precipitated 30 Ml of each lysate 
with 1ml of 10% (vol/vol) TCA and protein pellets were further dissolved in 150 Ml 
NaOH (1 N, 37 °C) and pH-adjusted by adding 50 Ml of 0.33 N HCl. Three 
50-Ml aliquots were each added to 10 ml of Ultima Gold XR (Perkin Elemer) 
scintillation fluid and read by a liquid scintillation counter. We obtained cpm per Mg 
of protein by dividing the average cpm of triplicates by protein amount (Mg) 
measured with Bradford kit (Bio-Rad). Lysates were also added to 3× loading 
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SDS-PAGE gel, fixed in 3% glycerol/10% glacial acetic acid/20% methanol (all 
(vol/vol)) for 1 h and stained with EZblue solution (Sigma) to confirm the equal 
loading. Gels were then dried completely (80 °C for 2.5 h) and exposed to a storage 
phosphor screen for 3 d. [35S] autoradiographs were scanned to ImageQuant 5.0 
(GE Healthcare) with a PhosphorImager (Molecular Dynamics).
Live-cell imaging and fluorescence recovery after photobleaching (FRAP). E18 
hippocampal neurons were transfected with a destabilized GFP containing a 
myristoylation sequence and further fused to 3` UTR of B-actin (dGFPmyr-bACT 
3` UTR) and d2-mCherry constructs (at ratio 4.5:3) using Amaxa nucleofection. 
The beta-actin 3` UTR drives axonal expression of dGFP26 and the myristoyla-
tion sequence restrict side diffusion of the GFP on translation. For live imaging, 
transfected neurons on 35-mm bottom glass dishes (MatTek) were washed and 
switched to pre-equilibrated Hibernate E Low Fluorescence medium (Brain Bits 
LLC). FRAP was performed using a Zeiss LSM5 upright confocal microscope fitted 
with a heating stage and 63× water-immersion objective (numeric aperture = 0.9). 
Pinhole was set to ~7.05 for 488 line and ~6.33 for 568 line (corresponding 
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that the highest pixel intensity is just saturating. Chosen axons were first pre-
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7.86 s per scan with a 52.3-s interval over a 20-min course. For guidance cue stimu-
lation, pre-aggregated Fc or ephrin-A1–Fc was added at 5 Mg ml−1 final concentra-
tion immediately before imaging and FRAP. For the study of translation inhibition, 
neurons were pretreated with 100 MM of anisomycin or DMSO for 20 to 30 min 
before FRAP study. Fluorescence intensity was measured using ImageJ and statistic 
analyses were performed in Prism 5 using two-way ANOVA to compare significant 
signal recovery over the course of treatment and among different treatments.
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